- Home
- BCAB vs GBIO Comparison
BCAB vs GBIO Comparison
Compare BCAB & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- GBIO
- Stock Information
- Founded
- BCAB 2007
- GBIO 2016
- Country
- BCAB United States
- GBIO United States
- Employees
- BCAB N/A
- GBIO N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- GBIO Health Care
- Exchange
- BCAB Nasdaq
- GBIO Nasdaq
- Market Cap
- BCAB 31.5M
- GBIO 29.5M
- IPO Year
- BCAB 2020
- GBIO 2020
- Fundamental
- Price
- BCAB $0.72
- GBIO $5.95
- Analyst Decision
- BCAB Hold
- GBIO Buy
- Analyst Count
- BCAB 3
- GBIO 4
- Target Price
- BCAB $1.00
- GBIO $10.67
- AVG Volume (30 Days)
- BCAB 1.1M
- GBIO 75.1K
- Earning Date
- BCAB 11-06-2025
- GBIO 11-05-2025
- Dividend Yield
- BCAB N/A
- GBIO N/A
- EPS Growth
- BCAB N/A
- GBIO N/A
- EPS
- BCAB N/A
- GBIO N/A
- Revenue
- BCAB $11,000,000.00
- GBIO $21,230,000.00
- Revenue This Year
- BCAB N/A
- GBIO N/A
- Revenue Next Year
- BCAB N/A
- GBIO N/A
- P/E Ratio
- BCAB N/A
- GBIO N/A
- Revenue Growth
- BCAB N/A
- GBIO 61.15
- 52 Week Low
- BCAB $0.24
- GBIO $3.00
- 52 Week High
- BCAB $2.53
- GBIO $29.10
- Technical
- Relative Strength Index (RSI)
- BCAB 56.79
- GBIO 52.30
- Support Level
- BCAB N/A
- GBIO N/A
- Resistance Level
- BCAB $0.84
- GBIO $6.25
- Average True Range (ATR)
- BCAB 0.07
- GBIO 0.30
- MACD
- BCAB -0.00
- GBIO -0.30
- Stochastic Oscillator
- BCAB 85.96
- GBIO 91.82
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.